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CORRELATION OF SERUM URIC ACID WITH PRECLINICAL 
TARGET ORGAN DYSFUNCTION IN HYPERTENSIVE 
POPULATION 
 
Introduction: 
 
 
Serum uric acid (SUA) plays a role in the development of cardiovascular 
morbidity in the general population, 1–4 as well as in patients with hypertension, 
5–7
 type II diabetes,8 and cardiac or vascular diseases as illustrated by a 
number of studies. A meta-analysis of data taken from 8 trials that were 
performed on hypertensive patients showed that each standard deviation (SD) 
increment in SUA entails an augmentation of cardiovascular risk that equals 
what is observed for similar changes in blood pressure or total cholesterol.9 
However, the independent role of SUA as a risk factor has been undergoing 
debate for years. In fact, mild hyperuricemia is often a concomitant finding of 
obesity, lipid abnormalities, and insulin resistance, all of which are 
components of the metabolic syndrome (MS). Accordingly, in some studies on 
white as well as Asian populations, the direct relationship that is observed 
between uric acid and cardiovascular mortality weakens or disappears after 
adjusting for confounding factors.10 
Several pathophysiological mechanisms linking SUA to cardiovascular 
damage at the cellular and tissue level have been proposed, including 
proliferation of vascular smooth muscle cells,11 stimulation of the inflammatory 
pathway,12 and possible prothrombotic effects mediated by platelet 
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activation.13 In addition, uric acid has proved to be an excellent marker for 
tissue ischemia and endothelial dysfunction14 and it has been shown to play a 
role in the development of atherosclerotic lesions.
15
 
The presence of sub-clinical hypertensive organ damage signals a condition 
of increased risk for cardiovascular, renal,  morbidity and mortality. Thus, the 
search for left ventricular hypertrophy (LVH), carotid atherosclerosis, and 
microalbuminuria, which are likely to reflect both the severity of blood 
pressure load and other non-hemodynamic risk factors, is currently 
recommended as part of global risk assessment.
16
 Because the role of SUA in 
the development of cardiovascular disease is receiving growing attention, a 
better understanding of its relationship with sub-clinical hypertensive target 
organ damage (TOD) may help clarify the pathophysiological mechanism(s) 
underlying this association. 
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AIM OF THE STUDY 
To evaluate the correlation between serum uric acid levels (SUA) and the 
presence and degree of pre-clinical organ damage in hypertensive population. 
TYPE OF STUDY 
Cross sectional study 
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 LITERATURE REVIEW 
Uric acid, a product of purine metabolism, is degraded in most mammals by 
the hepatic enzyme, urate oxidase (uricase), to allantoin, which is freely 
excreted in the urine. However, during the Miocene epoch (2 to 5 million years 
ago), 2 parallel but distinct mutations occurred in early hominoids that 
rendered the uricase gene nonfunctional. As a consequence, humans and the 
great apes have higher uric acid levels (>2 mg/dl) compared with most 
mammals (<2 mg/dl).  
Uric acid levels also vary significantly within humans as the result of factors 
that increase generation (such as high purine or protein diets, alcohol 
consumption, conditions with high cell turnover, or enzymatic defects in purine 
metabolism) or decrease excretion. A reduction in glomerular filtration rate 
(GFR) increases serum uric acid, although a significant compensatory 
increase in gastrointestinal excretion occurs.20 Hyperuricemia also may result 
from increased net tubular absorption. After filtration, uric acid undergoes both 
reabsorption and secretion in the proximal tubule, and this process is 
mediated by a urate/anion exchanger and a voltage-sensitive urate 
channel.
21,22
 Organic anions such as lactate decrease urate secretion by 
competing for urate through the organic anion transporter, whereas several 
substances, including probenecid and benziodarone, have opposite 
effects.23Hyperuricemia is usually defined as >6.5 or 7.0 mg/dL in men and 
>6.0 mg/dL in women.  
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Hyperuricemia Is Increased in Subjects at Cardiovascular Risk 
Serum uric acid is frequently elevated in subjects at cardiovascular risk24 Uric 
acid is higher in men and postmenopausal women because estrogen is 
uricosuric.
25
 In subjects with obesity, insulin resistance, and dyslipidemia ("the 
metabolic syndrome"), hyperuricemia frequently occurs because insulin 
stimulates sodium and urate reabsorption in the proximal tubule.
25
 Uric acid is 
increased in subjects with renal disease as the result of reduction in GFR and 
renal urate excretion. Diuretics, such as thiazides, increase serum uric acid by 
stimulating both sodium and urate reabsorption in the proximal tubule. Alcohol 
intake results in elevated uric acid levels due to increased urate generation 
(from increased adenine nucleotide turnover) and decreased excretion (due to 
lactate blocking tubular transport of urate).26,27 
Uric acid is also commonly associated with hypertension. It is present in 25% 
of untreated hypertensive subjects, in 50% of subjects taking diuretics, and in 
>75% of subjects with malignant hypertension.28 The increase in serum uric 
acid in hypertension may be due to the decrease in renal blood flow that 
accompanies the hypertensive state, since a low renal blood flow will 
stimulate urate reabsorption.
29
 Hypertension also results in micro vascular 
disease, and this can lead to local tissue ischemia.
30
 In addition to the release 
of lactate that blocks urate secretion in the proximal tubule, ischemia also 
results in increased uric acid synthesis.
31
 With ischemia, ATP is degraded to 
adenine and xanthine, and there is also increased generation of xanthine 
oxidase. The increased availability of substrate (xanthine) and enzyme 
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(xanthine oxidase) results in increased uric acid generation as well as oxidant 
(O2-) formation. The finding that ischemia results in an increased uric acid 
levels may account for the increase seen  in preeclampsia
32
 and congestive 
heart failure.
33
 Other factor, which may also contribute to as why uric acid is 
associated with hypertension, includes alcohol abuse,
34
 lead intoxication,
35
 
obesity and insulin resistance, and diuretic use.  
The observation that an elevated uric acid is associated with subjects at 
cardiovascular risk may account for hyperuricemia predicting the development 
of cardiovascular disease in the general population, in subjects with 
hypertension, and in subjects with preexisting cardiovascular disease.  
Hyperuricemia also predicts stroke in diabetic and non-diabetic subjects36,37 
and predicts the development of hypertension
38,39,40
 and renal disease in the 
general population.
41
 In these studies, uric acid may be simply "marking" 
subjects at increased cardiovascular and renal risk42,43 Consistent with this 
hypothesis, many studies have found that uric acid is not an independent risk 
factor for cardiovascular disease after controlling these other risk factors. 
Hyperuricemia is therefore considered benign unless associated with gout or 
kidney stones.
44
 Nevertheless, some studies find uric acid predictive for the 
development of cardiovascular disease, hypertension, and renal disease 
despite associated risk factors. This raises the possibility that uric acid may 
have a pathogenic role in hypertension and cardiovascular disease. Indeed, 
recently soluble uric acid has been recognized to not be inert but rather to 
have several biological actions that could either be beneficial or detrimental to 
humans. 
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Uric Acid as an Antioxidant: A Protective Factor in Cardiovascular 
Disease?  
An important observation was that uric acid might function as an antioxidant, 
and possibly one of the most important antioxidants in plasma.
45,46,47
 Urate 
(the soluble form of uric acid in the blood) can scavenge superoxide, hydroxyl 
radical, and singlet oxygen and can chelate transition metals. Peroxynitrite is 
a particularly toxic product formed by the reaction of superoxide anion with 
nitric oxide that can injure cells by nitrosylating the tyrosine residues 
(nitrotyrosine formation) of proteins. Uric acid can also block this reaction.48 
Recently, Hink et al
49
 reported that uric acid might also prevent the 
degradation of extracellular superoxide dismutase (SOD3), an enzyme critical 
in maintaining endothelial and vascular function. SOD3 is an extracellular 
enzyme that catalyzes the reaction of superoxide anion (O2-·) to hydrogen 
peroxide (H2O2). The removal of O2-· by SOD3 prevents the reaction and 
inactivation by O2-· of the important endothelial vasodilator, nitric oxide (NO). 
SOD3, by removing O2-·, therefore helps to maintain NO levels and maintain 
endothelial function. Normally, SOD3 is inactivated in the presence of H2O2, 
suggesting a feedback inactivation of the enzyme. However, uric acid blocks 
SOD inactivation by H2O2 by regenerating SOD3 with the production of a 
urate radical. This latter radical, although potentially a pro-oxidant, has been 
found to be markedly less reactive than classic oxidants and can be rapidly 
regenerated back to urate in the presence of ascorbate.
50
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Ames et al
45
 hypothesized that the uricase mutation occurred during early 
hominoid evolution because the antioxidant action of uric acid may have 
provided an evolutionary advantage and that this may have accounted for the 
greater longevity of humans and the great apes compared with most other 
primates. The increase in serum uric acid in subjects with cardiovascular 
disease might therefore reflect a compensatory mechanism to counter the 
oxidative stress that occurs in these conditions.
51
 However, this does not 
readily explain why higher uric acid levels in patients with cardiovascular 
disease are generally associated with worse outcomes 
Is Uric Acid a Mediator of Hypertension and Renal Disease?  
Endothelial dysfunction, local oxidant generation, elevated circulating 
cytokines, and a pro inflammatory state are common in patients with 
cardiovascular disease.
52
 Endothelial dysfunction is often demonstrated by 
showing an impaired NO release in response to acetylcholine, which results in 
impaired endothelium-dependent vasodilatation. Oxidants may cause 
endothelial dysfunction by reacting with and removing the NO. The 
observation that xanthine oxidase generates oxidants and uric acid in settings 
of tissue ischemia potentially explains why uric acid is associated with 
endothelial dysfunction and oxidative stress in conditions such as heart failure 
and diabetes.
53,54,55
 Hyperuricemia is also associated with the activation of 
circulating platelets, which also may reflect endothelial dysfunction.
56
 
Allopurinol, which inhibits xanthine oxidase and hence blocks both uric acid 
and oxidant formation, can reverse the impaired endothelial NO production in 
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both heart failure and type 2 diabetes.
53,54,55
 Allopurinol has also been 
reported to reduce cardiovascular complications after coronary artery 
bypass57,58 and in patients with dilated cardiomyopathy.59 Although the 
beneficial effects correlate with the lowering of uric acid in some of these 
studies, most authorities have hypothesized that the beneficial effect of 
allopurinol is to reduce oxidative stress. 
Uric acid may contribute to endothelial dysfunction.  Waring et al 60have 
reported that uric acid infusion in healthy humans resulted in impaired 
acetylcholine-induced vasodilatation in the forearm, thereby documenting 
impaired endothelial NO release. Serum uric acid and serum nitric oxide 
levels also vary during the day in a reciprocal pattern, suggesting a pattern of 
physiological regulation.61 Recent studies in experimental animal models have 
also found that mild hyperuricemia inhibits the nitric oxide system in the 
kidney (see below).  
The mechanism by which uric acid impairs endothelial function is not known. 
However, whereas uric acid is considered an antioxidant, it is also pro-
oxidative under certain conditions, especially when other antioxidants are at a 
low level62,63 
Uric Acid, Vascular Smooth Muscle Cell Proliferation, and Inflammation 
Uric acid also stimulates rat vascular smooth muscle cell proliferation in 
vitro.64, 65,66,67,68 Vascular smooth muscle cells do not express a receptor for 
uric acid but rather have organic anion transporters that allow urate uptake.68 
Once inside the vascular smooth muscle cell, uric acid activates specific 
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mitogen activated protein kinases (Erk1/2) with the de novo induction of 
cyclooxygenase-2 (COX-2), local thromboxane formation, and with 
upregulation of platelet-derived growth factor A (PDGF A) and C-chain and 
PDGF- receptor mRNA The uric acid induced cell proliferation can be 
inhibited by blocking any member of this pathway. 
Soluble uric acid is proinflammatory. Uric acid stimulates synthesis of 
monocyte chemo attractant protein-1 (MCP-1) in rat vascular smooth muscle 
cells by activating p38 MAP kinase and the nuclear transcription factors, NF-B 
and AP-1.69 MCP-1 is a chemokine that is important in vascular disease and 
atherosclerosis.70 Soluble uric acid also stimulates human mononuclear cells 
to produce interleukin-1ß, interleukin-6, and tumor necrosis factor (TNF). 71 
Infusion of uric acid into mice also leads to a marked increase in circulating 
TNF- levels.72  
Experimental Models: Hypertension in Hyperuricemic Rats 75 
Recently, mild hyperuricemia was developed in rats through the  use of a 
uricase inhibitor (oxonic acid). Unlike previous hyperuricemic  models, this 
model was associated with no urate crystal  deposition in the kidney and 
relatively preserved renal function. A remarkable observation, now 
documented by two different laboratories,  was that systemic hypertension 
developed in hyperuricemic rats  after several weeks. The hypertension was 
associated  with increased renin and a decreased neuronal nitric oxide 
synthase  (NOS1) in the juxtaglomerular apparatus. The hypertension  was 
prevented by administration of an ACE inhibitor and to a  lesser extent by L-
arginine (a substrate for nitric oxide),  thereby confirming a key role for renin-
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angiotensin and NOS  systems in the blood pressure elevation. Hypertension 
and  changes in rennin, NOS1 were prevented by maintaining  uric acid levels 
in the normal range with allopurinol or benziodarone  (a uricosuric). 
Hyperuricemic rats were also shown to have salt sensitivity  (that is, a greater 
increase in blood pressure for the same  sodium load compared with normal 
rats). An explanation for  the mechanism comes from studies in other 
experimental models  that have shown that salt sensitivity may result from 
preglomerular  vascular disease.  Experimental models associated with 
preglomerular  vascular disease have renal ischemia, leading to the infiltration  
of leukocytes into the interstitium that generate local oxidants,  altering the 
balance of local vasoregulatory factors favoring  vasoconstriction, and 
resulting in a reduction in sodium excretion,  a shift in pressure natriuresis, 
and an increase in blood pressure.  Elements of this pathway have been 
demonstrated in a variety  of animal models, and the salt sensitivity can be 
prevented  or ameliorated by interrupting this pathway. 
Consistent with this pathway of salt sensitivity, chronically  hyperuricemic rats 
have thickening and hypercellularity of the  afferent arteriole of the 
glomerulus, with inward hypertrophic  vascular remodeling, leading to an 
increase in medial thickness  and a reduction in lumen diameter. The 
arteriolopathy occurs  independent of blood pressure, although it is dependent 
on the  renin-angiotensin system. In concert with the development  of pre-
glomerular vascular disease, rats manifest subtle tubulo-interstitial  
inflammation and fibrosis. Once these renal changes develop,  salt sensitivity 
can be shown. At this point, the kidney is  driving salt sensitivity because 
correction of the elevated  uric acid level is no longer protective. 
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Experimental Hyperuricemia and Renal Injury75:  
Renal injury also occurred in hyperuricemic rats, consisting of  afferent 
arteriolopathy, mild tubulo-interstitial fibrosis, glomerular  hypertrophy, and 
eventually, glomerulosclerosis and albuminuria.  Micropuncture studies 
documented that this is associated with  an increase in glomerular hydrostatic 
pressure. The renal  changes are prevented if serum uric acid is maintained in 
the  normal range with allopurinol.  
Experimental hyperuricemia also accelerated injury in established  models of 
renal disease. Hyperuricemia exacerbated cyclosporine  nephropathy in rats, 
resulting in worse tubulo-interstitial  injury and arteriolar hyalinosis with 
increased renin and a  greater loss of macula densa NOS1 and renal NOS3 
expression. Hyperuricemia also accelerated progression in the remnant 
kidney  model and resulted in higher blood pressure, more proteinuria,  
worser renal function, and more glomerulosclerosis and tubulo-interstitial  
fibrosis. These rats also had severe vasculopathy, involving  the interlobular 
artery and afferent arteriole with de novo  expression of COX-2 in the blood 
vessels and increased renal  renin expression. The renal changes were 
significantly improved  by reducing uric acid levels with allopurinol.   
Do the Experimental Studies Provide New Insights? 75 
The observation that hyperuricemic animals have salt sensitivity  and 
increased blood pressure provided an additional mechanism  to explain why 
the uricase mutation occurred in early hominoid  evolution. Thus, the uricase 
mutation may have provided an evolutionary  advantage to early hominoids by 
maintaining blood pressure under  the low sodium dietary conditions of that 
period. 
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The observation that experimental hyperuricemia caused hypertension,  
intrarenal vascular disease, renal disease, and vascular inflammation  in rats 
might also provide the long-sought pathogenic mechanism  by which uric acid 
could cause cardiovascular disease in humans.   
Is there evidence that uric acid causes hypertension in humans?   
Epidemiological studies showed a continuous relation of serum uric acid with 
blood pressure that is stronger in younger subjects  with some dampening 
over time, which is consistent with  the experimental studies that 
demonstrated that once sufficient  renal injury occurred, animals developed 
salt-sensitive hypertension  regardless of the uric acid levels. Hyperuricemia 
is also  an independent risk factor for predicting the development of  
hypertension. To date, no studies have examined  whether lowering uric acid 
will reduce blood pressure in hypertensive  humans, but it should be noted 
that the above studies suggest  that lowering uric acid would be more 
effective at preventing  rather than treating hypertension, for once the 
intrarenal vascular  disease develops, the hypertension would then be 
expected to  be driven by the kidney. Hyperuricemia also correlated with  
plasma renin activity, and renal renin expression is also  increased in 
hyperuricemic rats. 
Does uric acid cause renal disease in humans? 
 Patients with  gout frequently have renal dysfunction (25% to 40% of cases),  
with histologic injury in the majority. The renal lesion consists  of variable 
degrees of arteriolosclerosis, glomerulosclerosis,  and interstitial fibrosis, often 
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with focal deposition of urate  crystals in the outer medulla.  Many authorities 
have ascribed  the renal lesion to coexistent hypertension or aging-associated  
renal disease.  However, this type of analysis cannot account  for all of the 
renal injury observed. 
Recently, an elevated uric acid predicted  the development of renal 
insufficiency in individuals with normal  renal function. Uric acid is an 
independent predictor for  progression in IgA nephropathy. Hyperuricemia 
also correlates  with the development of renal dysfunction in type II diabetes 
and independently predicts progression in renal transplant patients  on 
cyclosporine.  In contrast, it remained unclear if uric acid is a risk factor  for 
progression in subjects with established renal disease.  Although 
experimental studies suggest uric acid may act as a  risk factor for 
progression, in the MDRD study, uric acid  was not found to be a risk factor.  
Furthermore, whereas some  studies report an improvement in renal function 
with the lowering  of uric acid in gouty subjects, others have not been  able to 
confirm these findings. 
How about the role of uric acid in mediating the systemic inflammatory  
response and endothelial dysfunction in humans?  
As discussed  earlier, uric acid infusion into humans causes endothelial 
dysfunction, and allopurinol improves endothelial dysfunction in subjects  with 
congestive heart failure or diabetes. Uric acid  also stimulates the production 
of cytokines from leukocytes  and chemokines from vascular smooth muscle 
cells. This suggests  a potential role for uric acid or for xanthine oxidase in 
mediating  the systemic inflammatory response that is linked to cardiovascular  
events.   
 15
Thus, in experimental and in vitro systems, uric acid appears to have the 
ability to induce inflammatory and vascular mechanisms that may contribute 
to rather than protect against the development of cardiovascular disease. The 
in vivo role of serum uric acid as an independent risk factor for cardiovascular 
and renal morbidity is controversial. A better understanding of its relationship 
with pre-clinical organ damage may help clarify the mechanism(s) implicated 
in the development of early cardiovascular disease. A number of studies have 
shown that serum uric acid plays a role in the development of cardiovascular 
morbidity in the general population, as well as in patients with hypertension, 
type II diabetes, and cardiac or vascular diseases. A meta-analysis of data 
taken from 8 trials that were performed on hypertensive patients showed that 
each standard deviation (SD) increment in SUA entails an augmentation of 
cardiovascular risk that equals what is observed for similar changes in blood 
pressure or total cholesterol. However, the independent role of SUA as a risk 
factor has been undergoing debate for years. In fact, mild hyperuricemia is 
often a concomitant finding of obesity, lipid abnormalities, and insulin 
resistance, all of which are components of the metabolic syndrome (MS). 
Accordingly, in some studies on white as well as Asian populations, the direct 
relationship that is observed between uric acid and cardiovascular mortality 
weakens or disappears after adjusting for confounding factors. The presence 
of sub-clinical hypertensive organ damage signals a condition of increased 
risk for cardiovascular and renal, morbidity and mortality. Thus, the search for 
left ventricular hypertrophy (LVH), carotid atherosclerosis, and 
microalbuminuria, which likely reflect both the severity of blood pressure load 
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and other non-hemodynamic risk factors, is currently recommended as part of 
global risk assessment. Because the role of SUA in the development of 
cardiovascular disease is receiving growing attention, a better understanding 
of its relationship with sub-clinical hypertensive target organ damage (TOD) 
may help clarify the pathophysiological mechanism(s) underlying this 
association. The present study was therefore performed to evaluate the 
association between SUA levels and the presence and degree of pre-clinical 
organ damage in a group of patients with essential hypertension.  
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MATERIALS AND METHODS 
100 patients with recently diagnosed (within six months) hypertension 
attending the outpatient clinic of our institution during the study period of 
January 2004 to December 2005  were included in this study.  Diagnosis of 
essential hypertension was made after complete medical history, physical 
examination, and routine biochemical analysis of blood and urine. 
Hypertension was defined according to the JNC VII guidelines. 
Exclusion criteria: 
1. Patients older than 70 years 
2.  Hypertension duration > 6 months 
3.  Diabetes mellitus 
4.  Cardiac failure 
5. Chronic kidney disease  
6. Patients on diuretics, ACE inhibitors, Angiotensin receptor 
blockers 
7. Secondary hypertension  
Five patients were lost to follow up, 2 patients were excluded as they had 
dilated cardiomyopathy, and 3 patients were excluded as their creatinine 
clearance was below 60ml/min. 
A written informed consent was obtained from all patients. History regarding 
the duration of hypertension, the medications being taken, coexisting medical 
problems, and symptomatology suggestive of ischemic heart disease, 
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transient ischemic attacks and that of renal involvement were documented.  
A detailed history of smoking (pack years / smoking index) and alcoholism 
(number of alcohol units per week was recorded; 1 alcohol unit=300 ml of 
beer, 100 ml of wine, or 30 ml of liquor) was obtained. A family history of 
cardiovascular and renal disease was noted. An overall clinical examination 
was done to exclude major co-morbidities. Examination of the heart and the 
peripheral pulses including the carotids were made. Abdominal examination 
was done to look for renal bruit. The blood pressure was measured at the time 
of enrollment. The average of their BP recorded in the last 6 months, if 
present was noted. With the patient in a seated position and after a 5-minute 
rest, BP was measured on the right arm with a mercury sphygmomanometer 
(cuff size, 12.5x40 cm). The systolic pressure and diastolic pressure were 
read to the nearest 2 mm Hg. The blood pressure was graded as  
• Good control (systolic BP <140 and diastolic BP <90) 
• Fair control (systolic BP 140-160 and diastolic BP 90 – 100) 
• Poor control (systolic BP >160 and diastolic BP >100). 
The presence, type, and extent of hypertensive retinopathy were investigated 
in a darkened room and under pupil dilatation. Direct ophthalmoscopy was 
carried out with an ophthalmoscope. The first arteriovenous crossing at least 
one disc diameter from the disc in each quadrant was selected and assessed 
for the presence of focal arteriolar narrowing, hemorrhages, exudates, and 
papilledema. Retinal lesions were classified according to the Keith-Wagner-
Barker classification. BMI was calculated with the following formula:  
BMI = weight (kg)/ height2(m). 
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Waist and hip measurements were made as per the ATP III guidelines. The 
Waist: Hip ratio was then calculated. A basic neurological examination was 
made to exclude focal neurological deficits. The standard laboratory testing 
for blood glucose, urea, serum creatinine, potassium was done. Creatinine 
clearance was estimated using the Cockcroft–Gault formula
17
and ideal body 
weight was used in the formula. Lipid profile was done for all the patients. The 
LDL cholesterol was calculated using the Friedwald equation. The ratio 
between total cholesterol and HDL was noted. Urine was examined for protein 
(using dipstick) and screened under the microscope for deposits. A baseline 
standard 12 lead ECG was taken. Left ventricular hypertrophy was calculated 
using the Romhilt -Estes scoring system (RE score) as shown below  
Largest R / S wave in limb lead > 20 mm or S 
wave in V1/V2 or R wave in V5/V6 > 30 mm 
3 
Strain pattern (without digoxin) 3 
Left atrial enlargement 3 
Left axis deviation 2 
QRS duration > 0.09 sec 1 
Intrinsicoid deflection > 0.05 sec 1 
 
A score greater than 5 was taken to indicate left ventricular hypertrophy. 
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Microalbuminuria: 
All patients were subjected to a spot urine microalbumin test using the radio 
immunoassay kit. An Albumin creatinine ratio was calculated (lab standard 
Adults < 30mcg/mg creatinine).  
Echocardiogram: 
Echocardiograms were obtained at rest with patients supine in the left lateral 
position, using standard parasternal and apical views (Fig.1). LV mass was 
derived using the formula described by Devereux and associates:  
LV mass (grams)=0.80x1.04 [(VSTd+LVIDd+PWTd)3-(LVIDd)3]+0.6 
• VSTd is ventricular septal thickness at end diastole 
• LVIDd is LV internal dimension at end diastole 
• PWTd is LV posterior wall thickness at end diastole 
LV mass was corrected for height2.7 (LVMI), and expressed in units of 
grams/meter (g/m2.7). The presence of left ventricular hypertrophy was 
defined for LVMI >51 g/m2.7 in either gender18.  
Carotid Ultrasound Scan 
The intima-media thickness (IMT) of both carotid arteries was evaluated by 
US scan as described by Weldelhag19 The carotid artery was scanned at the 
bifurcation and at the common carotid artery (CCA). At each longitudinal 
projection the far-wall IMT was measured at the distal end of the CCA, 10 mm 
caudally to the point where the near and far walls lose their parallel 
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configuration. A carotid IMT greater than 10 mm was considered abnormal. 
Each measurement was calculated by taking the average of three readings. 
As the measurements were done by a single individual inter-observer 
variations were minimized (Fig.2). 
Serum Uric Acid levels (SUA): 
Serum uric acid was calculated using the enzymatic calorimetric test with the 
normal range for adult males being 3.6 – 7 and for adult females being 2.3 – 
6.1. Hyperuricemia was defined as SUA > 7 in males and SUA > 6 in females.  
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RESULTS OF DESCRIPTIVE STATISTICS 
 
 
1. Age distribution: 
Characteristics Mean (years) Distribution (years) 
Age 45 30 - 68 
 
 
2. Sex distribution: 
Sex Numbers (%) 
Male 51 (57%) 
Female 39  (43%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 1 Sex Distribution
57%
43%
Male
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3. Menopausal status: 
Menopausal state Numbers (%) 
Attained Menopause 12 (30%) 
Not attained menopause 27 (70%) 
 
 
4. Blood pressure distribution: 
Average Blood pressure Numbers (%) 
Systolic < 140 and diastolic < 90 21 (23%) 
Systolic 140 - 160 or diastolic 90 - 100 45 (50%) 
Systolic > 160 or diastolic > 100 24 (27%) 
  
 
 
 
 
 
 
 
 
 
 
 
 
Graph 2 Blood pressure Distribuiton
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5. Smoking or alcohol habits: 
Habits Numbers (%) 
Yes 24 (27%) 
No  66 (73%) 
Smokers 15 (62%) 
Alcoholics 9 (38%) 
 
 
 
 
 
 
 
 
 
 
 
6. Family history of vascular events: 
Family history Numbers (%) 
Positive 15(17%) 
Negative 75 (83%) 
 
 
 
Graph 3 Smoking and alchol habits
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7. Body Mass Index distribution: 
Characteristics Numbers 
BMI (mean) 23.42 + 5.3 
BMI (range) 15 - 35 
BMI 25 – 30- overweight 9 (10%) 
BMI > 30 - obesity 15 (16%) 
 
8. Waist circumference and Waist Hip ratio Distribution: 
Characteristics Numbers 
Waist circumference (mean) 88 cm + 11.1 
Waist circumference (range) 60 -122 cm 
Waist Hip ratio (mean) 0.97 + 0.1 
Waist Hip ratio (range) 0.81 – 1.21 
Waist circumference > 90 cm (males) 12 (23% of males) 
Waist circumference > 80 cm  (females) 27 (69% of females) 
 
9. Lipid distribution: 
Characteristics Numbers 
Total cholesterol (mean) 194.8 mg/dl + 29 
Total cholesterol (range) 150 – 272 mg/dl 
HDL cholesterol (mean; range) 39.5 mg/dl + 3.4; 35 – 47 mg/dl 
Total cholesterol: HDL ratio (mean; range) 4.97 + 0.9; 3.3 – 7.16 
HDL cholesterol < 40 (males) 24 (47% of males) 
HDL cholesterol < 50 (females) 39 (All the females) 
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10. Hypertensive retinal changes: 
Keith Wagner grading Numbers (%) 
Grade I 9(10%) 
Grade II 69(77%) 
Grade III 12(13%) 
Grade IV 0 
 
 
 
 
 
 
 
 
 
 
 
 
11. ECG evidence of left ventricular hypertrophy: 
Romhilt Estes score Numbers (%) 
<= 5 81 (90%) 
> 5 9 (10%) 
 
 
Graph 4 Hypertensive retinopathy changes
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12. Urine Albumin excretion: 
Characteristics Numbers (%) 
Urine albumin excretion (mean) 
(mcg/mg creatinine) 
26.8 + 39   
Urine albumin excretion (range) 
(mcg/mg creatinine) 
2.5 – 160 
Microalbuminuria present  24 (26%) 
 
 
13. Left ventricular mass index distribution: 
Characteristics Numbers (%) 
LV mass index (mean)  51.8 + 6.5 
LV mass index (range) 44 - 65 
LV mass index > 51 
(left ventricular hypertrophy) 
46 (51%) 
LV mass index < 51 44 (49%) 
 
 
14. Carotid intima media thickness distribution: 
Characteristics Numbers (%) 
Carotid IMT > 1 mm (abnormal) 39 (43%) 
Carotid IMT < 1 mm 51 (57%) 
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15. Serum uric acid distribution: 
Characteristics Numbers (%) 
Serum uric acid levels (mean) 5.46 + 1.75 
Serum uric acid levels (range) 1.75 – 9.60 
Uric acid > 6 (females) 12 (31% of females) 
Uric acid > 7 (males) 10 (20% of males) 
 
Graph 8 Distribution of Uric acid levels
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CORRELATION OF URIC ACID LEVELS WITH VARIOUS 
PARAMETERS AND STATISTICAL SIGNIFICANCE 
 
1. Correlation of age with uric acid and indices of target organ 
damage: 
 
Characteristic Uric acid Microalbuminuria LV mass index Carotid IMT 
Age - 0.157 
(p = 0.139) 
-.024 
(p = -0.822) 
0.147 
(p = 0.166) 
0.328 
(p = 0.002) 
 
 
Age did not significantly influence the other indices of target organ 
damage like microalbuminuria, LV mass index. There was a positive 
correlation between age and the carotid IMT (correlation coefficient 0.328), 
however age did not significantly influence uric acid levels  
(cc -0.157). 
 
2. Correlation of sex and uric acid: 
 
Characteristic Sex N Mean uric acid levels SD t-test 
Male 51 5.7110 1.70863 
Uric acid 
Female 39 5.1218 1.76679 
t=1.6 
p=0.11 
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3. Correlation of menopausal state with uric acid: 
 
Characteristic N Mean uric acid levels SD t- test 
Post menopausal 12 5.5787 1.46871 
Pre menopausal 27 5.0189 1.86605 
F-1.2 
p=0.3 
 
 
The sex did not statistically influence the levels of uric acid (p = 0.11). Among 
the female patients there was no significant difference in the uric acid levels 
between pre-menopausal and post-menopausal groups (p = 0.3) 
 
4. Correlation of family history of vascular events with uric acid 
levels: 
Characteristic 
Family history 
Vascular 
events 
N Mean uric acid levels SD t-test 
Yes 6 6.0433 1.68856 
Uric acid 
No 84 5.4137 1.75549 
T=0.85 
p=0.39 
 
The levels of uric acid was not statistically significant between patients who 
had a positive family history for vascular events and those who did not  
(p =0.39). 
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5. Correlation of habituation to smoking / alcohol to uric acid levels: 
 
Characteristic 
Smoker_ 
alcoholic N 
Mean uric 
acid levels SD F-test 
Yes 24 5.9342 1.91753 
Uric acid 
No 66 5.2817 1.66502 
F-1.6 
p=0.11 
 
 
The levels of uric acid were not influenced significantly by addiction to alcohol 
or smoking (p = 0.11) 
 
 
6. Correlation of average blood pressure with uric acid levels: 
 
Grade of BP control N Mean uric 
acid levels SD F-test 
1 SBP < 140 and DBP < 90 21 5.1029 1.35 
2 SBP 140 – 160 or DBP > 90-100 45 5.3227 1.711 
3 SBP >160 or DBP > 100 24 6.0138 2.04 
F-1.8 
p=0.17 
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7. Correlation of blood pressure control with target organ damage: 
 
Characteristic Target organ damage 
Correlation coefficient 
(p value) 
Microalbuminuria 0.508 (0.0001) 
LV mass index 0.457 (0.0001) 
Average Blood 
pressure 
Carotid IMT 0.359 (0.001) 
 
 
The average degree of blood pressure control correlated positively with the 
target organ damage, microalbuminuria (cc 0.508), LV mass index (cc 0.457) 
and carotid IMT (cc 0.359). There was no statistically significant correlation 
with uric acid levels (p = 0.17). Interestingly the degree of blood pressure 
control had a negative correlation with the waist circumference (cc -0.238). 
The patients with poorer control (systolic > 160 or diastolic > 100) had greater 
waist circumference. 
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8a. Correlation of components of metabolic syndrome with uric acid 
and target organ damage: 
Characteristic 
Uric Acid 
(cc / p 
value) 
Microalbuminuria 
(cc / p value) 
LV mass 
index 
(cc / p 
value) 
Carotid 
IMT 
(cc / p 
value) 
BMI  0.11  (p = 0.303) 
0.024  
(p = 0.82) 
0.003  
(p = 0.981) 
0.035  
(p = 0.743) 
Waist 
circumference 
0.068  
(p = 0.524) 
0.167  
(p = 0.115) 
0.181  
(p = 0.08) 
0.155  
(p = 0.145) 
Total cholesterol 0.115  (p = 0.281) 
0.117  
(p = 0.274) 
0.258  
(p = 0.014) 
0.223  
(p = 0.035) 
HDL cholesterol -0.049  (p = 0.647) 
-0.158  
(p = 0.137) 
-0.145  
(p = 0.174) 
-0.064  
(p = 0.549) 
 
 
8b. Correlation of Waist circumference with uric acid levels: 
Characteristic 
Waist 
circumference N 
Mean uric 
acid levels SD t-test 
Abnormal 40 5.6513 1.77706 
Uric acid 
Normal 50 5.3578 1.74160 
T=0.75 
p=0.46 
 
The levels of serum uric acid levels did not correlate with body mass index  
(p = 0.3), waist circumference (p= 0.52), waist hip ratio (p = 0.7), and the 
indices of target organ damage also did not statistically correlate with body 
mass index, waist circumference and waist hip ratio. The total cholesterol 
levels correlated positively with carotid IMT (cc 0.253) and LV mass index  
(cc 0.258) but does not correlate with serum uric acid levels (p = 0.28). 
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9. Correlation of parameters of target organ damage with uric acid 
levels: 
 
 
Characteristic LV mass Index N 
Mean uric acid 
levels SD t-test 
Normal 44 4.7264 1.24977 
Uric acid 
Abnormal 46 6.1533 1.88155 
T=4.22 
p=0.001 
Characteristic  Carotid IMT N 
Mean uric acid 
levels 
SD t-test 
Normal 51 4.7582 1.49633 
Uric acid 
Abnormal 39 6.3677 1.64688 
T=4.84 
p=0.001 
Characteristic  
Microalbumin 
uria 
N 
Mean uric acid 
levels 
SD t-test 
Normal 66 5.1038 1.58699 
Uric acid 
Abnormal 24 6.4233 1.84050 
T=3.34 
p=0.001 
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10. Correlation of uric acid levels with number of target organs 
involved: 
Number of target 
organs involved N 
Mean uric acid 
levels SD Std. Error 
0 37 4.6070 1.17858 
1 19 5.2563 1.88615 
2 12 6.3633 1.64519 
3 22 6.5600 1.75021 
F=8.83 
p=0.001 
 
 
 
 
 
 
 
 
 
 
 
 
Uric acid levels correlated significantly with target organ damage indices 
(p=0.001). The correlation of uric acid was with LV mass index (cc 0.496) was 
the strongest when compared with that of microalbuminuria (cc 0.413) and 
carotid IMT (cc 0.427). Serum uric acid levels positively correlated with 
number of target organs involved. The greater the number of organs involved 
the higher the uric acid levels (p= 0.001). 
Graph 13 Correlation of SUA with TOD 
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DISCUSSION OF RESULTS 
Studies done on the association between serum uric acid levels and the 
presence and degree of target organ damage are not many.  Two studies 
done in Italy by Francesca Viazzi etal studied the relation of uric acid and 
target organ damage. The first study  investigated the relationship between 
pulse pressure and sub clinical cardiovascular damage in a cohort of 
unselected middle-aged patients with untreated primary hypertension (Pulse 
pressure and sub clinical cardiovascular damage in primary hypertension-
Francesca Viazzi etal 73). The second study aimed to evaluate the association 
between uric acid levels and the presence and degree of pre clinical organ 
damage in a group of middle-aged, untreated patients with essential 
hypertension Serum Uric Acid and Target Organ Damage in Primary 
Hypertension Francesca Viazzi etal 74. The results of the present study is 
compared with the above two studies. Similar studies have not been 
undertaken in centers in our country.  
1a. Comparative Descriptive statistics (Age; Sex) 
Parameters Study on 
SUA and TOD 
(n = 425) 
Study on SUA and 
Pulse  Pressure 
(n = 333) 
Current study 
(2006) 
(n = 90) 
265 204 51 Sex(male) 
      (Female) 160 129 39 
Age (yrs) 47±9 47±0.5 (20–66) 45.4 + 9.49 
(30 - 68) 
Premenopausal (nos.) NA NA 27 
Postmenopausal 
(nos.) 
NA NA 12 
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1b. Comparative Descriptive statistics (Family history of 
vascular events; smoking; alcohol; BMI; lipids) 
Parameters Study on SUA 
and TOD 
(n = 425) 
Study on SUA 
and PP 
(n = 333) 
Current study 
(2006) 
(n = 90) 
Family history vascular 
events (%) 
NA 52 16 
Smokers (%) NA 63 62 
Alcohol (%) NA 29 38 
BMI kg /m2 26.4 ± 3.6 17–38 (26 ± 0.2) 15–35 
(23 + 5.3) 
Total Cholesterol mg/dl 211.13 ± 1.11 213 ± 2.5 150–272 
(194.8 + 29) 
HDL Cholesterol mg/dl 52.97 ± 0.36 52 ± 0.9 35–47 
(39.5 + 3.4) 
Prevalence of 
Metabolic syndrome 
components (%) 
21 NA NA 
 
The average age of patients in the study was 45.4, which was 
comparable to the above Italian studies. This study also divided the 
female population into the pre menopausal and the postmenopausal 
groups to study if there existed any difference in their cardiovascular 
and renal target organ damage. However no significant difference was 
found between the two groups and the mean uric acid levels did not 
vary (5.01 and 5.17 respectively in premenopausal and 
postmenopausal) in the two groups. A family history of cardiovascular 
events was positive in a high number of patients in the study from Italy1 
(52%) when compared to the present study (16%). This could be due to 
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the lack of awareness and accessibility of pre-symptomatic health 
screening as well as lack of knowledge regarding the symptomatology 
of various cardiovascular, cerebrovascular, renal events in our 
population. The numbers of smokers and alcoholics were comparable. 
The BMI among the Indian population appear to be lesser than their 
Italian counterparts. The presence of malnutrition makes BMI a poor 
marker of health risk in our country. The trend towards using the 
abdominal circumference as an indicator of vascular risk has been 
popularized among the Asian population. The mean total cholesterol 
was higher among the Italian population, however it is to be noted that 
the HDL cholesterol was at a higher level in these population1 (52 vs 
39). All the women included in the study did not have protective levels 
of HDL cholesterol (> 50) and hence had one component of metabolic 
syndrome as per the ATPIII guidelines. However a formal comparison of 
patients with and without metabolic syndrome was not done in this 
study. The prevalence of metabolic syndrome in the Italian study was 
21%.  
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1c. Comparative descriptive statistics:  
Parameters 
Study on 
SUA and TOD 
(data on female 
population) 
Study on 
SUA and PP 
(n = 333) 
Current study 
(n = 90) 
Uric acid (mg/dl) 5.14 + 0.13 5.1 + 0.1 5.46 + 1.75 
ECG – LVH evidence (%) 13 NA 10 
LV mass index 52 + 2.8 51 + 0.7 51.81 + 6.53 
 LVH – ECHO evidence (%) 43 NA 51 
Carotid IMT (mm) NA 0.68 + 0.01 1.13 
Carotid abnormalities (%) 30 NA 43 
 
The mean uric acid levels were comparable among both the population, 
5.1 among the Italians and 5.4 among the Indians. Electrocardiographic 
evidence for LVH was found in 10 % in the present study, while 
Echocardiographic evidence was present in 51%. The figures are 
comparable with the Italian studies. The mean LV mass index was 
comparable between the two populations. The mean carotid IMT was 
1.13 among the study population while it was 0.68 in the Italian group. 
Carotid abnormalities were seen in 43% of the study population, higher 
than the Italian studies (30%). This may be due to a higher prevalence 
of carotid atherosclerosis in Asian population. 
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2. Correlation of uric acid with target organ damage 
(Comparative statistics) 
Parameters 
Study on 
SUA and TOD  
(n = 425) 
Study on 
SUA and PP 
(n = 333) 
Current study 
(n = 90) 
Age  Not significant P < 0.0001 Not significant 
Gender NA P = 0.04 P = 0.11 
HDL cholesterol P = 0.02 NA P = 0.647 
Microalbuminuria P = 0.02 P = 0.03 P = 0.001 
LV mass index P = 0.002 P < 0.0001 P = 0.001 
Carotid IMT  P = 0.015 P < 0.0001 P = 0.001 
Number of target 
organs involved  
P = 0.02 NA P = 0.001 
 
Serum uric acid levels were correlated with various variables that affected the 
target organ damage in hypertensive population. Age and sex did not have 
any significant effect on the uric acid levels, which was also observed in the 
Italian studies. While HDL cholesterol had a negative correlation with uric acid 
levels it was not found to be statistically significant. HDL cholesterol correlated 
with uric acid levels in the Italian studies. In this study serum uric acid 
correlated significantly with pre clinical target organ dysfunction  (i.e.) 
microalbuminuria, LV mass index and carotid intima media thickness (IMT).  
These findings were similar to the Italian studies, which had also reported a 
strong association between uric acid levels and pre clinical organ dysfunction. 
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Among the target organ dysfunction the strongest correlation was observed 
between SUA and left ventricular mass index.  This confirmed results from 
previous studies that showed a robust association of uric acid with 
electrocardiographic abnormalities and coronary atherosclerosis. It is to be 
noted that confounding factors like age, sex, alcoholism, smoking, BMI, Waist 
circumference, Waist Hip ratio and dyslipidemia did not correlate with uric acid 
levels, further suggesting uric acid as an independent marker of 
cardiovascular and renal abnormalities. Another highlight of the study was the 
correlation of uric acid levels with the number of target organs involved. This 
is similar to the report by Francesca Viazzi etal that found a statistically 
significant relation between the uric acid levels and number of target organs 
involved. The graphical results were compared (Graphs 13 and 14). 
The association between SUA and early hypertensive and 
atherosclerotic organ damage is intriguing and suggests that mild 
hyperuricemia might be a marker of incipient cardiovascular involvement. The 
other aspect brought out by the study was the positive correlation between the 
average blood pressure control and the influence on the target organ damage. 
Though it did not correlate with serum uric acid levels, it did emphasize the 
point that target organ dysfunction primarily depends on adequacy of blood 
pressure control. This has been emphasized by previous studies by 
Francesca etal 73,74. The role of increased pulse pressure in the context of 
cardiovascular risk assessment and stratification is currently receiving 
growing attention.  Furthermore, elevated pulse pressure values, measured 
both in the office and by 24-h ambulatory monitoring, have been linked to the 
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presence of sub clinical cardiovascular damage, i.e. left ventricular 
hypertrophy, increased carotid wall thickness, and microalbuminuria, as well 
as to structural changes in the resistance vasculature at the peripheral levels.  
It has been suggested that high pulse pressure levels reflect the degree of 
stiffness of the arterial tree, regardless of whether they are caused by 
increased systolic (SBP) and/or reduced diastolic pressure (DBP). It was 
interesting to observe that the degree of blood pressure control had a 
negative correlation with the waist circumference. Insulin resistance could 
explain this relation and in the context of primary hypertension, mild 
hyperuricemia is often a feature of insulin resistance and the metabolic 
syndrome. The current study however did not show any correlation between 
the metabolic syndrome components (Waist circumference, waist hip ratio, 
dyslipidemia) and uric acid levels. However a formal comparison was not 
done between patients who had metabolic syndrome and those who did not. 
The results suggested that uric acid might be implicated in the early 
pathogenetic stages of cardiovascular damage. They also provide a 
pathophysiological rationale to at least partly account for the association of 
uric acid to cardiovascular events and mortality in hypertensive patients. In 
fact, sub clinical TOD represents an intermediate step between exposure to 
risk factors and occurrence of overt cardiovascular disease and has 
previously been shown to be a strong predictor of major events. Several 
mechanisms have been proposed to account for the association between 
SUA and cardiovascular and renal abnormalities, and include: (1) increased 
uric acid production to counteract oxidative stress and endothelial damage in 
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the context of the atherosclerotic process (2) the severity of hypertension 
itself; and (3) a subtle reduction in glomerular filtration rate leading to impaired 
renal uric acid clearance. The issue of mild hyperuricemia and cardiovascular 
disease has  been getting more and more attention since anti-hypertensive 
agents were shown to possibly induce subtle but significant changes in uric 
acid, which could impact on their ability to provide cardiovascular and renal 
protection. In conclusion the present study showed that increased SUA was a 
marker of preclinical TOD in a population of patients with primary 
hypertension. 
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CONCLUSIONS 
• Age, sex, menopausal state did not affect the serum uric acid levels 
• The levels of uric acid were not statistically significant between patients 
who had a positive family history for vascular events and those who did 
not. 
• The levels of uric acid were not influenced significantly by alcohol or 
smoking 
• The average degree of blood pressure control correlated positively with 
the target organ damage, microalbuminuria, LV mass index and carotid 
IMT. There was no statistically significant correlation with uric acid levels  
• The degree of blood pressure control had a negative correlation with the 
waist circumference.  
• The levels of serum uric acid levels did not correlate with body mass 
index, waist circumference, waist hip ratio, and the indices of target organ 
damage also did not statistically correlate with body mass index, waist 
circumference and waist hip ratio. 
• The total cholesterol levels correlated positively with carotid IMT and LV 
mass index but did not correlate with serum uric acid levels. 
• Uric acid levels correlated significantly with target organ damage indices. 
The correlation of uric acid was with LV mass index was the strongest 
when compared with that of microalbuminuria and carotid IMT. Serum uric 
acid levels positively correlated with number of target organs involved. The 
greater the number of organs involved the higher the uric acid levels. 
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SUMMARY 
The role of serum uric acid as an independent risk factor for 
cardiovascular and renal morbidity is controversial. A better understanding of 
its relationship with pre-clinical organ damage may help clarify the 
mechanism(s) implicated in the development of early cardiovascular disease.  
The present study aimed to evaluate the correlation between serum uric acid 
levels and the presence and degree of pre-clinical organ damage in 
hypertensive population. 100 patients with recently diagnosed hypertension 
attending the outpatient clinic of our institution were studied. Albuminuria, Left 
ventricular mass index and carotid intima-media thickness were assessed for 
all patients. Uric acid levels correlated significantly with target organ damage 
indices. The correlation of uric acid was with LV mass index was the strongest 
when compared with that of microalbuminuria and carotid IMT. Serum uric 
acid levels positively correlated with number of target organs involved. 
However the direct relationship between uric acid and target organ damage 
was weakened by factors like dyslipidemia and degree of control of blood 
pressure, which also determined the target organ dysfunction.  
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FUTURE DIRECTIONS 
Whether SUA is an independent, modifiable marker or a surrogate 
marker of TOD needs to be studied. Further studies are needed to ascertain 
whether SUA reduction per se confers cardiovascular protection, and the 
possible role it may play as a surrogate end point of anti-hypertensive 
treatment.  
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ABBREVIATIONS 
 
SUA  - Serum uric acid 
TOD – Target organ damage 
LVH – Left Ventricular hypertrophy 
IMT – Intima media thickness 
BP – Blood pressure 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
PP – Pulse pressure 
SD – Standard Deviation 
US – Ultrasound 
BMI – Body mass index 
WHR – Waist Hip ratio 
cc – Correlation co-efficient 
CCA – Common carotid artery  
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PROFORMA 
Name  
Age  
Sex M/F (If Female Menopause attained   Y / N) 
HTOP No. 
DM Y / N 
CKD Y/ N 
CAD / MI / DCM      Y / N 
Diuretic use   Y / N 
Duration of HT 
Average BP in past 3 mon. 
CVA   Y / N 
Angina / MI       Y / N 
Visual disturbance    Y / N  
Oliguria    Y / N 
Nocturia   Y / N 
Pedal edema   Y / N 
Abdominal pain   Y / N 
Burning micturition   Y / N 
Co-morbid conditions: 
Smoker type / quantity / duration 
Alcohol type / quantity / duration 
Family H /o DM / SHT / CAD / CVA / Renal Disease  
Examination: 
Height               Weight                   Waist                      Hip 
Pulse                       
Peripheral pulses 
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Carotids equal / unequal  
BP (upper limb) 
Fundus   
Arteriolar narrowing   Y / N 
AV changes    Y / N 
Hemorrhages / cotton wool spots    Y / N 
Papilledema    Y / N 
CVS  
Per Abdomen:  
Bruit:           Y / N 
Aneurysm:      Y / N 
Neurological exam (focal neurological deficit) Y / N  
Blood Glucose (fasting) 
Urea 
Serum creatinine 
Lipid profile 
Urine protein       sugar             deposits 
ECG (RE score) -  
Echocardiogram 
Carotid intima media thickness: 
Albumin creatinine ratio 
Serum uric acid 
Comments: 
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1 Ambika 38 F N 2 No Yes 153 50 21.36 80 66 1.21 2 190 35 5.43 > 90 2 11 5.07 0.8 45
2 Haridas 59 M NA 2 Yes Nil 163 58 21.83 92 98 0.94 2 201 45 4.47 > 90 2 28.9 3.14 1.4 58
3 Anandhi 38 F N 2 No Yes 153 50 21.36 80 66 1.21 2 190 35 5.43 > 90 2 11 5.07 0.8 45
4 Bakyaraj 39 M NA 3 Yes Nil 166.5 66 23.81 76 68 1.12 2 172 38 4.53 > 90 2 57.31 9.6 1.4 65
5 Karna 40 M NA 2 No No 160 88 34.38 78 88 0.89 2 150 35 4.29 > 90 4 59 7 1.4 55
6 Balaraman 39 M NA 3 Yes Nil 166.5 66 23.81 76 68 1.12 2 172 38 4.53 > 90 2 57.31 5.64 1.4 65
7 Balasubramani 45 M NA 2 No No 165 63 23.14 88 94 0.94 2 272 38 7.16 > 90 2 2.76 4.62 1 50
8 Hussain 59 M NA 2 Yes Nil 163 58 21.83 92 98 0.94 2 201 45 4.47 > 90 2 28.9 7.5 1.4 58
9 Balu 45 M NA 2 No No 165 63 23.14 88 94 0.94 2 272 38 7.16 > 90 2 2.76 4.62 1 50
10 Amaravathy 38 F N 2 No Yes 153 50 21.36 80 66 1.21 2 190 35 5.43 > 90 2 11 5.07 0.8 45
11 Gopal 41 M NA 3 Yes No 168 58 20.55 88 90 0.98 2 190 40 4.75 > 90 2 37.26 6.79 1.5 59
12 Madasamy 44 M NA 2 Yes Nil 165 45 16.53 88 90 0.98 2 220 35 6.29 > 90 3 59.3 6.81 1.4 65
13 Kodhandaraman 42 M NA 2 Nil Yes 164 60 22.31 88 91 0.97 2 190 44 4.32 > 90 2 36.34 4.35 1.3 50
14 Ravi 47 M NA 2 Yes No 160 56 21.88 85 92 0.92 2 201 39 5.15 > 90 2 <3.48 4.95 1 45
15 Harikrishnan 59 M NA 2 Yes Nil 163 58 21.83 92 98 0.94 2 201 45 4.47 > 90 2 28.9 3.14 1.4 58
16 Basha 39 M NA 3 Yes Nil 166.5 66 23.81 76 68 1.12 2 172 38 4.53 > 90 2 57.31 5.64 1.4 65
17 Krishna 40 M NA 2 No No 160 88 34.38 78 88 0.89 2 150 35 4.29 > 90 4 59 7 1.4 53
18 Karthikeyan 42 M NA 2 Nil Yes 164 60 22.31 88 91 0.97 2 190 44 4.32 > 90 2 36.34 7 1.3 50
19 Madhavan 40 M NA 1 Nil Nil 157 57 23.12 84 88 0.95 2 214 35 6.11 > 90 2 < 4.59 5.09 1 45
20 Kamarajan 42 M NA 2 Nil Yes 164 60 22.31 88 91 0.97 2 190 44 4.32 > 90 2 36.34 4.35 1.3 50
21 Ponnayan 60 M NA 1 Yes Nil 165 45 16.53 83 81 1.02 1 188 45 4.18 > 90 1 < 10.67 3.71 1 45
22 Vijaya 45 F N 1 Nil No 160 84 32.81 104 119 0.87 1 200 38 5.26 > 90 2 211.53 9 1.5 60
23 Lakshman 54 M NA 1 No Nil 159 55 21.76 89 94.5 0.94 2 175 40 4.38 > 90 1 9.18 6.32 1.1 50
24 Michael raj 44 M NA 2 Yes Nil 165 45 16.53 88 90 0.98 2 220 35 6.29 > 90 3 59.3 8.8 1.4 65
25 Lawerence 54 M NA 1 No Nil 159 55 21.76 89 94.5 0.94 2 175 40 4.38 > 90 1 9.18 6.32 1.1 50
26 Madhesh 40 M NA 1 Nil Nil 157 57 23.12 84 88 0.95 2 214 35 6.11 > 90 2 < 4.59 5.09 1 45
27 Ramesh 47 M NA 2 Yes No 160 56 21.88 85 92 0.92 2 201 39 5.15 > 90 2 <3.48 4.95 1 45
28 Madivanan 40 M NA 1 Nil Nil 157 57 23.12 84 88 0.95 2 214 35 6.11 > 90 2 < 4.59 5.09 1 45
29 Raju 40 M NA 1 No No 168 50 17.72 85 86 0.99 2 150 45 3.33 > 90 3 < 6.19 5.22 0.9 45
30 Balakrishnan 45 M NA 2 No No 165 63 23.14 88 94 0.94 2 272 38 7.16 > 90 2 2.76 4.62 1 50
31 Syed Khajaji 31 M N 2 No Yes 175 73 23.84 91 98 0.93 2 185 42 4.40 > 90 0 9.49 6.48 1 51
32 Lokeshwar Rao 54 M NA 1 No Nil 159 55 21.76 89 94.5 0.94 2 175 40 4.38 > 90 1 9.18 6.32 1.1 50
33 Namratha 47 F Y 2 No No 145 55 26.16 105 110 0.95 2 170 35 4.86 > 90 2 8.19 3.6 1 50
34 Shaffee 30 M NA 3 Yes No 174 67 22.13 96 96 1.00 3 256 38 6.74 > 90 2 56 7 1.3 65
35 Jalaja 56 F Y 1 No No 159 59 23.34 94 87 1.08 3 180 40 4.50 > 90 3 <4.06 5.64 1 51
36 Parasuraman 60 M NA 1 Yes Nil 165 45 16.53 83 81 1.02 1 188 45 4.18 > 90 1 < 10.67 3.71 1 45
37 Vidya 45 F N 1 Nil No 160 84 32.81 104 119 0.87 1 200 38 5.26 > 90 2 211.53 5.22 1.5 60
38 Rajiv 40 M NA 1 No No 168 50 17.72 85 86 0.99 2 150 45 3.33 > 90 3 < 6.19 5.22 0.9 45
39 Gokul 41 M NA 3 Yes No 168 58 20.55 88 90 0.98 2 190 40 4.75 > 90 2 37.26 6.79 1.5 59
40 Vittal rao 55 M NA 2 No No 150 36 16.00 82 79 1.04 2 175 35 5.00 > 90 2 13.11 3.17 1 45
41 Ramar 68 M NA 3 Yes Yes 172 80 27.04 103 111 0.93 2 210 40 5.25 > 90 2 58.3 3.89 1.5 58
42 Karuppan 40 M NA 2 No No 160 88 34.38 78 88 0.89 2 150 35 4.29 > 90 4 59 7 1 51
43 Ramasamy 40 M NA 3 No No 157.5 39 15.72 60 74 0.81 2 164 47 3.49 > 90 6 145 7.8 1.3 55
44 Veera 55 M NA 2 No No 150 36 16.00 82 79 1.04 2 175 35 5.00 > 90 2 13.11 3.17 1 45
45 Rakesh 47 M NA 2 Yes No 160 56 21.88 85 92 0.92 2 201 39 5.15 > 90 2 <3.48 4.95 1 45
46 Deepa 43 F N 2 No No 150 50 22.22 85 94 0.90 2 213 44 4.84 60-90 2 2.4 6.2 1 50
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47 Lalitha 41 F N 2 No Nil 152 52 22.51 89 75 1.19 2 215 40 5.38 > 90 7 2.5 1.75 1 51
48 Saritha 60 F Y 3 No Nil 150 35 15.56 80 85 0.94 1 200 35 5.71 > 90 1 60.82 4.34 1.2 57
49 Ragamadulla 68 M NA 3 Yes Yes 172 80 27.04 103 111 0.93 2 210 40 5.25 > 90 2 58.3 8 1.5 58
50 Pavithra 35 F N 2 Nil Nil 145 65 30.92 75 90 0.83 2 150 40 3.75 > 90 4 45 6 1.3 55
51 Malar 40 F N 1 Nil No 168 73 25.86 94 110 0.85 2 170 40 4.25 > 90 2 < 6.19 3.26 0.9 44
52 Saleem 31 M N 2 No Yes 175 73 23.84 91 98 0.93 2 185 42 4.40 > 90 0 9.49 6.48 1 51
53 Sarika 60 F Y 3 No Nil 150 35 15.56 80 85 0.94 1 200 35 5.71 > 90 1 60.82 4.34 1.2 57
54 Venkatesh 55 M NA 2 No No 150 36 16.00 82 79 1.04 2 175 35 5.00 > 90 2 13.11 3.17 1 45
55 Jessica 41 F N 2 No Nil 152 52 22.51 89 75 1.19 2 215 40 5.38 > 90 7 2.5 1.75 1 51
56 Krishnaveni 38 F N 2 Nil Nil 150 74 32.89 92 112 0.82 2 205 40 5.13 > 90 6 12.87 6.78 0.9 44
57 Lakshmi 47 F Y 2 No No 145 55 26.16 105 110 0.95 2 170 35 4.86 > 90 2 8.19 3.6 1 50
58 Gnanambal 43 F N 2 No No 150 50 22.22 85 94 0.90 2 213 44 4.84 > 90 2 2.4 6.2 1 50
59 Jyothy 56 F Y 1 No No 159 59 23.34 94 87 1.08 3 180 40 4.50 > 90 3 <4.06 5.64 1 51
60 Sumathy 33 F N 3 No Yes 152 54 23.37 77 90 0.86 2 179 40 4.48 > 90 2 25 3.15 0.9 45
61 Meenakshi 56 F Y 2 No Nil 146 75 35.18 122 102 1.20 3 244 39 6.26 > 90 2 15.03 6.92 1 51
62 Kannamma 35 F N 2 Nil Nil 145 65 30.92 75 90 0.83 2 150 40 3.75 > 90 4 45 6 0.8 45
63 Noorinisa 56 F Y 2 No Nil 146 75 35.18 122 102 1.20 3 244 39 6.26 > 90 2 15.03 6.92 1 51
64 Sharmila 43 F N 2 No No 150 50 22.22 85 94 0.90 2 213 44 4.84 60-90 2 2.4 6.2 1 50
65 Kanmani 38 F N 2 Nil Nil 150 74 32.89 92 112 0.82 2 205 40 5.13 > 90 6 12.87 6.78 0.9 44
66 Saranya 33 F N 3 No Yes 152 54 23.37 77 90 0.86 2 179 40 4.48 > 90 2 25 3.15 0.9 45
67 Gopi 41 M NA 3 Yes No 168 58 20.55 88 90 0.98 2 190 40 4.75 > 90 2 37.26 7.5 1.5 59
68 Mohammed haris 30 M NA 3 Yes No 174 67 22.13 96 96 1.00 3 256 38 6.74 > 90 2 56 8.5 1.3 65
69 Latha 41 F N 2 No Nil 152 52 22.51 89 75 1.19 2 215 40 5.38 > 90 7 2.5 1.75 1 51
70 Kalyani 35 F N 2 Nil Nil 145 65 30.92 75 90 0.83 2 150 40 3.75 > 90 4 45 6 1.3 53
71 Kalaiselvi 47 F Y 2 No No 145 55 26.16 105 110 0.95 2 170 35 4.86 > 90 2 8.19 3.6 1 50
72 KhajaVali 31 M N 2 No Yes 175 73 23.84 91 98 0.93 2 185 42 4.40 > 90 0 9.49 6.48 1 51
73 Maragatham 40 F N 1 Nil No 168 73 25.86 94 110 0.85 2 170 40 4.25 > 90 2 < 6.19 3.26 0.9 44
74 Gnaneshwari 38 F N 2 Nil Nil 150 74 32.89 92 112 0.82 2 205 40 5.13 > 90 6 12.87 6.78 0.9 44
75 Bhuaneshwari 40 F N 1 Nil No 168 73 25.86 94 110 0.85 2 170 40 4.25 > 90 2 < 6.19 3.26 0.9 44
76 Sangeetha 55 F Y 3 No No 150 50 22.22 88 90 0.98 3 215 40 5.38 > 90 2 31.24 5.46 1.5 55
77 Ponny 56 F Y 1 No No 159 59 23.34 94 87 1.08 3 180 40 4.50 > 90 3 <4.06 5.64 1 51
78 Ruthina bai 56 F Y 2 No Nil 146 75 35.18 122 102 1.20 3 244 39 6.26 > 90 2 15.03 6.92 1 51
79 Parveen 60 M NA 1 Yes Nil 165 45 16.53 83 81 1.02 1 188 45 4.18 > 90 1 < 10.67 3.71 1 45
80 Satya 55 F Y 3 No No 150 50 22.22 88 90 0.98 3 215 40 5.38 > 90 2 31.24 5.46 1.5 55
81 Rajapriya 60 F Y 3 No Nil 150 35 15.56 80 85 0.94 1 200 35 5.71 > 90 1 60.82 8 1.2 57
82 Rajalakshmi 55 F Y 3 No No 150 50 22.22 88 90 0.98 3 215 40 5.38 > 90 2 31.24 7.6 1.5 55
83 Sridevi 33 F N 3 No Yes 152 54 23.37 77 90 0.86 2 179 40 4.48 > 90 2 25 3.15 0.9 45
84 Magesh kumar 44 M NA 2 Yes Nil 165 45 16.53 88 90 0.98 2 220 35 6.29 > 90 3 59.3 6.81 1.4 65
85 Naushad ahamed 30 M NA 3 Yes No 174 67 22.13 96 96 1.00 3 256 38 6.74 > 90 2 56 7 1.3 65
86 Vidya 45 F N 1 Nil No 160 84 32.81 104 119 0.87 1 200 38 5.26 > 90 2 211.53 5.22 1.5 60
87 Ramasamy 40 M NA 3 No No 157.5 39 15.72 60 74 0.81 2 164 47 3.49 > 90 6 145 8.8 1.3 54
88 Ramar 68 M NA 3 Yes Yes 172 80 27.04 103 111 0.93 2 210 40 5.25 > 90 2 58.3 3.89 1.5 58
89 Rajiv 40 M NA 1 No No 168 50 17.72 85 86 0.99 2 150 45 3.33 > 90 3 < 6.19 5.22 0.9 45
90 Ramasamy 40 M NA 3 No No 157.5 39 15.72 60 74 0.81 2 164 47 3.49 > 90 6 145 2.84 0.8 45
  
 
 
 
 
 
 
 
 
 
 
Graph 9 Correlation of Uric acid with Microalbuminuria (mcg/mg) 
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Graph 10  Correlation of Uric acid and Carotid IMT 
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Graph 11 Correlation of Uric acid with LV Mass index 
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Graph 5 Prevalence of Microalbuminuria 
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Graph 7 Carotid IMT
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Graph 12 Correlation Matrix between Uric acid and TOD 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 14 Compared statistics - study by Francesca Viazzi et al 
 
TOD 0, patients without signs of organ damage;  
TOD+, subgroup of patients with either LVH or carotid abnormalities 
or microalbuminuria;  
TOD++, patients with a combination of any two signs of TOD;  
TOD+++, those with all three signs of the TOD we examined. 
Graph 13 Correlation of SUA with TOD 
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